MKRN1 and in situ carcinoma: In 47 patients (25.1%) with CIN3/CIS, positive results were recorded as follows: cytology, 44 (93.6%); HPV assay, 46 (97.9%); MKRN1, 35 (74.5%); and p16INK4a, 36 (76.6%).